Remifentanil and control bleeding during lumbar fusion surgery

Comparative study of the effect of two different doses of remifentanil on bleeding control in lumbar fusion surgery under general anesthesia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200217046523N12

Enrollment

110

Registered

2021-03-09

Start date

2021-04-20

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal fusion surgery. Fusion with defective stereopsis

Interventions

Intervention 1: Intervention group 1: Patients in this group undergo vertebral fusion surgery under general anesthesia and receive remifentanil at a dose of 0.1 µg / kg. Patients' blood pressure and b

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patient consent to participate in the study Patient candidate for posterior spinal fusion surgery at levels 1 and 2 Not taking antihypertensive drugs

Exclusion criteria

Exclusion criteria: Changing the technique of operation and anesthesia for various reasons Unwanted hemodynamic complications due to surgical technique Severe cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Blood pressure. Timepoint: Every 30 minutes during surgery and recovery. Method of measurement: Measured by the device.;Bleeding. Timepoint: Every 30 minutes during surgery and recovery. Method of measurement: Count the number of gases.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Masoudifar

Esfahan University of Medical Sciences

masoudifar@med.mui.ac.ir+98 31 3337 7986

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026